Inferra AI / Company / RPRX
Royalty Pharma
RPRX · Health Care
Last earnings Aug 5, 2026
AI analysis
Q1 2026 · reported May 6, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, NY, May 6, 2026 Royalty Pharma plc (Nasdaq RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.”
“Raising financial guidance for full year 2026 (excludes contribution from future transactions) Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,325 million and $3,450 million (previously $3,275 million to $3,425 million), representing expected Royalty Receipts growth of 4% to 8%.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Royalty Pharma Press Release May 6, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows Provided May 6, 2026 Previous Portfolio Receipts $3,325 million to $3,450 million $3,275 million to $3,425 million Payments for operating and professional costs 5.5% to 6.5% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts.
Event summary
We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter, said Pablo Legorreta, Royalty Pharma s Chief Executive Officer and Chairman of the Board
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Company outlook: “htm EX-99.1 Document Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, NY, May 6, 2026 Royalty Pharma plc (Nasdaq RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.”
Company outlook: “Raising financial guidance for full year 2026 (excludes contribution from future transactions) Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,325 million and $3,450 million (previously $3,275 million to $3,425 million), representing expected Royalty Receipts growth of 4% to 8%.”
Company outlook — Raised (“Raised”)
“htm EX-99.1 Document Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, NY, May 6, 2026 Royalty Pharma plc (Nasdaq RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.”
Company outlook — Raised (“Raising”)
“Raising financial guidance for full year 2026 (excludes contribution from future transactions) Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,325 million and $3,450 million (previously $3,275 million to $3,425 million), representing expected Royalty Receipts growth of 4% to 8%.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Royalty Pharma Press Release May 6, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows Provided May 6, 2026 Previous Portfolio Receipts $3,325 million to $3,450 million $3,275 million to $3,425 million Payments for operating and professional costs 5.5% to 6.5% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma s existing notes and the quarterly interest payment schedule for the term loan assumed as part of the internalization transaction.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
These projections assume no additional debt financing in 2026, including no drawdown on the revolving credit facility.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Royalty Pharma Press Release May 6, 2026 3 Liquidity and Capital Resources Royalty Pharma s liquidity and capital resources are summarized below As of March 31, 2026, Royalty Pharma had cash and cash equivalents of $586 million and total debt with principal value of $9.2 billion.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
In the first quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $136 million in dividends and distributions.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
In January 2025, Royalty Pharma announced a share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Strategy & priorities
Food and Drug Administration (FDA) accepted for filing, with Priority Review, a supplemental Biologics License Application for Ziihera in combination regimens for the first line treatment of adult patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Based on these results, Revolution Medicines intends to submit the data to global regulatory authorities, including the FDA, as part of a future New Drug Application (NDA) under the Commissioner s National Priority Voucher program.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Examples include discussion of Royalty Pharma s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma s fundamental business strategy.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.
SEC original ↗Royalty Pharma — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
SEC original ↗Royalty Pharma — Earnings release (8-K exhibit)EX-99May 6, 2026
Legal Proceedings 55 Item 1A.
SEC original ↗Royalty Pharma — 10-Q Quarterly report10-QAug 5, 2026
These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
SEC original ↗Royalty Pharma — 10-Q Quarterly report10-QAug 5, 2026
In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report on Form 10-Q should not be regarded as a representation by us that our plans and business objectives will be achieved.
SEC original ↗Royalty Pharma — 10-Q Quarterly report10-QAug 5, 2026
Earnings deck slides
0 decks with slide viewRoyalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Royalty Pharma — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
60 documents- Q2 2026
- 10-QRPRX
Aug 5, 2026
- 8-KRPRX
Aug 5, 2026
- Q1 2026
- 8-KRPRX
Jun 4, 2026
- 8-KRPRX
May 28, 2026
- 10-QRPRX
May 6, 2026
- 8-KRPRX
May 6, 2026
- 8-KRPRX
Apr 13, 2026
- Q4 2025
- 10-KRPRX
Feb 11, 2026
- 8-KRPRX
Feb 11, 2026
- Q3 2025
- 8-KRPRX
Dec 22, 2025
- 8-KRPRX
Dec 22, 2025
- 10-QRPRX
Nov 5, 2025
- 8-KRPRX
Nov 5, 2025
- Q2 2025
- 8-KRPRX
Sep 16, 2025
- 8-KRPRX
Aug 13, 2025
- 10-QRPRX
Aug 6, 2025
- 8-KRPRX
Aug 6, 2025
- 8-KRPRX
Jul 17, 2025
- Q1 2025
- 8-KRPRX
May 19, 2025
- 8-KRPRX
May 12, 2025
- 10-QRPRX
May 8, 2025
- 8-KRPRX
May 8, 2025
- 8-KRPRX
Apr 11, 2025
- 8-KRPRX
Apr 10, 2025
- Q4 2024
- 10-KRPRX
Feb 12, 2025
- 8-KRPRX
Feb 11, 2025
- 8-KRPRX
Jan 13, 2025
- 8-KRPRX
Jan 10, 2025
- 8-KRPRX
Jan 10, 2025
- Q3 2024
- 8-KRPRX
Dec 31, 2024
- 8-KRPRX
Nov 6, 2024
- 10-QRPRX
Nov 6, 2024
- Q2 2024
- 8-KRPRX
Sep 27, 2024
- 8-KRPRX
Aug 8, 2024
- 10-QRPRX
Aug 8, 2024
- 8-KRPRX
Aug 7, 2024
- Q1 2024
- 8-KRPRX
Jun 20, 2024
- 8-KRPRX
Jun 10, 2024
- 8-KRPRX
Jun 6, 2024
- 8-KRPRX
Jun 4, 2024
- 8-KRPRX
May 29, 2024
- 8-KRPRX
May 9, 2024
- 10-QRPRX
May 9, 2024
- Q4 2023
- 8-KRPRX
Feb 15, 2024
- 10-KRPRX
Feb 15, 2024
- 8-KRPRX
Feb 6, 2024
- 8-KRPRX
Jan 8, 2024
- Q3 2023
- 8-KRPRX
Dec 27, 2023
- 8-KRPRX
Dec 27, 2023
- 8-KRPRX
Nov 16, 2023
- 8-KRPRX
Nov 8, 2023
- 10-QRPRX
Nov 8, 2023
- 8-KRPRX
Oct 19, 2023
- Q2 2023
- 8-KRPRX
Aug 8, 2023
- 10-QRPRX
Aug 8, 2023
- Q1 2023
- 8-KRPRX
Jun 23, 2023
- 8-KRPRX
May 9, 2023
- 10-QRPRX
May 9, 2023
- Q4 2022
- 8-KRPRX
Mar 28, 2023
- 8-KRPRX
Mar 15, 2023
Earnings releases
12 documentsPresentations
7 documents
Transcripts
0 documentsNo transcripts for Royalty Pharma are held in this edition of the library.
Mentioned by
14 companiesOther tracked companies whose held documents mention Royalty Pharma by name or ticker. A mention is counted once per document, from the document text the library holds.
Harmony Gold Mining Co Ltd (HMY)
“… ROYALTY PHARMA ANNOUNCES TRANSFORMATIVE STEP IN COMPANY’S EVOLUTION WITH ACQUISITION OF ITS EXTERNAL MANAGER AND $3 BILLION SHARE REPURCHASE PROGRAM •”
“…the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or sh”
Rentokil Initial Plc /Fi (RTO)
“ debt financing in 2025, including no drawdown on the revolving credit facility. In 2024, Royalty Pharma collected interest of $46 million on its cash and cash equivalents. … …redeployed into value-enhancing royalty acquisitions, used to repay ”
“…the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or sh”
“ internalization transaction and borrowings under our revolving credit facility. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million.… …$380 million term loan upon maturity. In the second quarter of 2026”
Alexandria Real Estate Equities (ARE)
“egarding: BeOne’s continued… …$50 million in expense, includes interest amortization from Royalty Pharma arrangement. • Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026,… …was $237”
“data corruption and significant disruption of our business operations.… … attributable to Royalty Pharma plc $ 294,690 $ 239,349 Earnings per Class A ordinary share: Basic $ 0.67 $ 0.55 Diluted $ 0.67 $ 0.55 Weighted average Class A ordinar”
“…the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or sh”
“…Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma's conference call on the acquisition of RP Management. I would now like to turn the call over to George Grofik, Senior Vice President, Head… …the”
Live Nation Entertainment (LYV)
“…the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or sh”
“egarding: BeOne’s continued… …$50 million in expense, includes interest amortization from Royalty Pharma arrangement. • Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026,… …was $227”
“vements Internalization Capital Deployment Returns Capital Allocation Authorized new $3… …Royalty Pharma retains significant financial capacity pay down debt or increase for royalty transactions dividend distributions Less attractive royalty opportun”
“potential commercialization… …$50 million in expense, includes interest amortization from Royalty Pharma arrangement. • Income tax outlook : earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026,… …an incre”
“least through the second quarter of 2029. · Financing included: … …our Royalty Pharma and Pharmakon agreements contingent upon FDA approval of obexelimab; and our cash guidance.. The forward-looking statements in this press release”
See also the earnings calendar for every tracked company’s next earnings date.